Viking Therapeutics Inc (US: VKTX) — Healthcare · Share Price, Chart & Market Data
About: Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $32.75 (-0.15%)
VKTXViking Therapeutics Inc
Loading watchlist status…
Trade VKTX now
Viking Therapeutics Inc share price
VKTX price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 9:31 am GMT+0
VKTX price performance
-3.107%
5D
0.707%
1M
-7.538%
YTD
26.253%
1Y
VKTX price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 9:31 am GMT+0
VKTX details
VKTX Market Signals